Inflammatory marker changes in a 24-month dietary and physical activity randomised intervention trial in postmenopausal women.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
14 12 2020
Historique:
received: 18 06 2020
accepted: 19 11 2020
entrez: 15 12 2020
pubmed: 16 12 2020
medline: 29 4 2021
Statut: epublish

Résumé

Chronic low-grade inflammation plays a role in the pathogenesis of several chronic diseases including cancer. Physical activity (PA) and diet have been supposed to modulate inflammatory markers. We evaluated the effects of a 24-month dietary and/or PA intervention on plasma levels of pro-inflammatory cytokines, a secondary analysis in the DAMA factorial trial. The 234 study participants (healthy postmenopausal women with high breast density, 50-69 years, non smokers, no hormone therapy) were randomised to four arms: (1) isocaloric dietary intervention mainly based on plant-foods; (2) moderate-intensity PA intervention with at least 1 h/week of supervised strenuous activity; (3) both interventions; (4) general recommendations on healthy dietary and PA patterns. Interleukins (IL)-1α, -1β, -6, tumor necrosis factor-α and C-reactive protein were measured at baseline and at the end of the intervention. Intention-to-treat-analyses were carried out using Tobit regression. Although all cytokines tended to increase over time, after 24 months women in the PA intervention (arms 2 + 3) showed lower levels of IL-1α (exp(β) = 0.66; p = 0.04) and IL-6 (exp(β) = 0.70; p = 0.01) in comparison with women in the control group (arms 1 + 4). No effects of the dietary intervention emerged. In healthy postmenopausal women with high breast density a moderate-intensity PA appears to slow the age-related increase of pro-inflammatory cytokines.

Identifiants

pubmed: 33318523
doi: 10.1038/s41598-020-78796-z
pii: 10.1038/s41598-020-78796-z
pmc: PMC7736293
doi:

Substances chimiques

Biomarkers 0
Cytokines 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

21845

Références

PLoS One. 2012;7(10):e46423
pubmed: 23110049
Environ Health Perspect. 2004 Dec;112(17):1691-6
pubmed: 15579415
JAMA. 2003 May 21;289(19):2545-53
pubmed: 12759326
Tumori. 2003 Nov-Dec;89(6):594-607
pubmed: 14870824
Angiology. 2015 Apr;66(4):304-18
pubmed: 24778424
Front Immunol. 2018 Apr 09;9:586
pubmed: 29686666
Metabolism. 2010 Jan;59(1):54-61
pubmed: 19709693
J Am Coll Cardiol. 2006 Aug 15;48(4):677-85
pubmed: 16904534
Endocr Metab Immune Disord Drug Targets. 2014;14(4):245-54
pubmed: 25244229
Nat Rev Immunol. 2011 Aug 05;11(9):607-15
pubmed: 21818123
Exp Gerontol. 2018 May;105:10-18
pubmed: 29275161
Cancer Causes Control. 2019 Oct;30(10):1113-1126
pubmed: 31392546
J Gerontol A Biol Sci Med Sci. 2006 Jun;61(6):575-84
pubmed: 16799139
Am J Clin Nutr. 2009 Jan;89(1):248-56
pubmed: 19056596
Med Sci Sports Exerc. 2010 Apr;42(4):701-7
pubmed: 19952829
Int J Cancer. 2009 Apr 1;124(7):1654-61
pubmed: 19085933
Breast Cancer Res Treat. 2011 Jun;127(2):555-63
pubmed: 21069450
Science. 2010 Dec 17;330(6011):1621
pubmed: 21163993
J Clin Oncol. 2016 Dec 10;34(35):4270-4276
pubmed: 27903155
Menopause. 2017 May;24(5):524-535
pubmed: 28002200
J Allergy Clin Immunol. 2011 Mar;127(3):701-21.e1-70
pubmed: 21377040
Arch Gerontol Geriatr. 2017 Nov;73:257-262
pubmed: 28866452
Cancer Res. 2012 May 1;72(9):2314-26
pubmed: 22549948
Circulation. 2000 Jul 4;102(1):42-7
pubmed: 10880413
Exerc Immunol Rev. 2006;12:6-33
pubmed: 17201070
Br J Nutr. 2015 Oct 14;114(7):999-1012
pubmed: 26228057
Ann Occup Hyg. 2007 Oct;51(7):611-32
pubmed: 17940277
Endocr Rev. 2002 Feb;23(1):90-119
pubmed: 11844745
Cancer Prev Res (Phila). 2016 Feb;9(2):196-203
pubmed: 26603740
Am J Med. 2006 Feb;119(2):166.e17-28
pubmed: 16443421
Nat Med. 2019 Dec;25(12):1822-1832
pubmed: 31806905
Cancer Prev Res (Phila). 2012 Jan;5(1):98-108
pubmed: 21982875
Obes Rev. 2013 Mar;14(3):232-44
pubmed: 23171381
Maturitas. 2002 Mar 25;41(3):187-92
pubmed: 11886764
Curr Opin Lipidol. 2009 Jun;20(3):182-9
pubmed: 19369869
Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1159-69
pubmed: 16775176
Nutr Metab Cardiovasc Dis. 2014 Sep;24(9):929-39
pubmed: 24787907
JAMA. 2004 Sep 22;292(12):1440-6
pubmed: 15383514
J Clin Invest. 2003 Jun;111(12):1805-12
pubmed: 12813013
Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):41-50
pubmed: 30068518
Tumori. 2014 Jul-Aug;100(4):377-85
pubmed: 25296586
J Lipid Res. 2007 Apr;48(4):751-62
pubmed: 17202130
Exerc Immunol Rev. 2011;17:6-63
pubmed: 21446352
Prz Menopauzalny. 2014 Jun;13(3):162-8
pubmed: 26327849
Med Sci Sports Exerc. 2009 Feb;41(2):297-305
pubmed: 19127197
Med Sci Sports Exerc. 2009 Aug;41(8):1533-9
pubmed: 19568208
Mediators Inflamm. 2008;2008:109502
pubmed: 19148295
Nutrition. 1999 Jun;15(6):523-6
pubmed: 10378216

Auteurs

G Masala (G)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, Florence, Italy. g.masala@ispro.toscana.it.

B Bendinelli (B)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, Florence, Italy.

C Della Bella (C)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

M Assedi (M)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, Florence, Italy.

S Tapinassi (S)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

I Ermini (I)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, Florence, Italy.

D Occhini (D)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, Florence, Italy.

M Castaldo (M)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, Florence, Italy.

C Saieva (C)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, Florence, Italy.

S Caini (S)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, Florence, Italy.

M M D'Elios (MM)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

D Palli (D)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH